

**Public Declaration of Interests and Confidentiality Undertaking  
of Swissmedic Medicines Expert Committee Members**

This document is aligned to the 'Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA) Scientific Committee members and experts' of the EMA.

**SECTION 1: PERSONAL DETAILS**

First Name Ulrich

Last Name Heininger

Organisation / Company University of Basel Childrens's Hospital

Country of Organisation /  
Company Switzerland

Committee

**I do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below.**

**Please specify the interests that you currently have (at the time of completion of the form) or have had within the past 5 years.**

### SECTION 2: PUBLIC DECLARATION OF INTERESTS

#### 2.1 Employment

☒ No ☐ Yes

Please indicate if you are employed / have been employed, either full or part time, either as paid or unpaid employee in pharmaceutical company.

Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

## 2.2 Consultancy

☐ No ☒ Yes

Choose "Yes" if there is any activity in which you provide or have provided advice or services regardless as to whether or not you received a fee for this activity. Please indicate all of them below.

Provision of advice or services to a pharmaceutical company (in a particular field such as the development of a product) regardless of contractual arrangements or any form of remuneration. (Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product)

Note: Conference / Seminar attendance is not considered as consultancy but should be indicated under Financial Interests, if subject to a fee / honoraria.

Period	Company	Product	Therapeutic Indication General Role / Area of Activity	Funding
08/2022 - 11/2022	GSK (Belgium)		Development of pertussis vaccines in general	
04/2020 - 11/2022	MSD (Switzerland)		Member of Advisory Board for Varicella	
07/2024 - TODAY	Takeda (Switzerland)	Dengue Vaccine	Vaccine against dengue (Task: Data Monitoring Committee)	
01/2017 - 01/2020	Watermark (USA) for Seqirus (Netherlands)	adjuvanted influenza vaccine	Vaccine against influenza (Task: Data Monitoring Committee)	
01/2020 - 06/2024	IQVIA (Ireland) for Seqirus (Netherlands)	cell culture based quadrivalent influenza vaccine	Vaccine against influenza (Task: Data Monitoring Committee)	
08/2019 - TODAY	No Pharmaceutical company but CEPI Funded Vaccine Trials		Vaccines against emerging infectious diseases (Task: Global Safety Overview)	
06/2022 - 06/2024	Takeda	Zika Virus Vaccine	Vaccine against Zika virus Zika Virus Vaccine (Task: Data Monitoring Committee)	

02/2023 - Sanofi (France)  
04/2023

Global expert panel on  
pertussis combo vaccines

07/2023 - Sanofi (France)  
10/2023

Advisory Board on Pertussis  
Disease and Prevention in Adult

05/2024 - Pfizer  
TODAY

Advisory Board on Lyme disease

06/2024 Moderna

Advisory board resp. tract  
infections

**2.3 Strategic Advisory Role**☒ No ☐ Yes

Choose "Yes" if you are participating or have participated in a (Scientific) Advisory Board/Steering Committee of a pharmaceutical company (e.g. board membership / directorship), with a right to vote on / influence the outcome of that body.

Participation (with a right to vote on/influence the outputs) in a (Scientific) Advisory Board/Steering Committee with the role of providing advice/expressing opinions on the (future) strategy, direction or development activities of a pharmaceutical company, either in terms of general strategy or product related strategy, regardless of contractual arrangements or any form of remuneration. Pharmaceutical company includes supply or service companies which contribute to the research, development, production and maintenance of a medicinal product.

Note: Involvement in Data Safety Monitoring Committees is not included in this category. Such involvement should be recorded under section 2.6 Principal Investigator. Involvement in clinical research should be listed under section 2.6 Principal Investigator or 2.7 Investigator as appropriate.

## 2.4 Current Financial Interests

☐ No ☒ Yes

Choose "Yes" if you have any financial interests currently held in a pharmaceutical company.

Financial interests relate to current holding of shares of a pharmaceutical company with the exclusion of independently managed investment funds/ pension. Compensation, fees, honoraria, salaries currently being paid directly to you by a pharmaceutical company, other than payment for expenses incurred with research work or re-imbursement of reasonable expenses incurred in relation to conference/seminar attendance (i.e. accommodation and travel costs).

Current is interpreted at time of completion of this form.

		X
Name of Pharmaceutical Company	Infectopharm (Deutschland)	
Financial Interest	Speaker fee for product independent postgraduate education	

		X
Name of Pharmaceutical Company	GSK (Switzerland)	
Financial Interest	Speaker fee for product independent postgraduate education	

		X
Name of Pharmaceutical Company	Astra Zeneca (Switzerland)	
Financial Interest	Speaker fee for product independent postgraduate education	

## 2.5 Patent

☒ No ☐ Yes

Choose "Yes" if any patent for a medicinal / competitor product is currently owned by either yourself or your institution and you are a beneficiary.

Current is interpreted at time of completion of this form.

## 2.6 Principal Investigator

☒ No ☐ Yes

Choose "Yes" if there are trials for which you are acting or have acted as Principal Investigator

Principal Investigator with the responsibility for the coordination of investigators at different centres participating in a multicentre trial or the leading investigator of a monocentre trial, or the coordinating (principal) investigator signing the clinical study report. This definition does not include a national coordinating investigator in a multinational trial. Involvement in Data Safety Monitoring Committee should be included in this section.



## 2.7 Investigator

☒ No ☐ Yes

Choose "Yes" if there are trials for which you are acting or have acted as Investigator.

Investigator involved in a clinical trial at a specific trial site who can be the responsible lead investigator of the trial at that specific site or a member of the clinical trial team who performs critical trial related procedures and makes important trial related decisions.

**2.8 Grant / Funding to organisation/institution**☒ No ☐ Yes

Choose "Yes" if any grants or other funding is currently received by your institutional unit from a pharmaceutical company and you receive no personal gain; or where your Organisation (e.g. Patient Organisation) receives a grant or other funding from a pharmaceutical company and you (irrespective if you are employed by the Organisation or are a volunteer) receive no personal gain.

Refers to a grant or other funding from a pharmaceutical company, currently being received (as far as the individual is aware) by an institution (please indicate funding to the smallest institutional unit) or an organisation (e.g. patient organisation), irrespective of whether or not the individual is employed or is a volunteer, and the individual receives no personal gain.

**2.9 Any other interests or facts**

☒ No ☐ Yes

Choose "Yes" if further to the interest declared above you have any other interests or facts that should be made known to Swissmedic, the Swiss Agency of Therapeutic Products and the public.

By choosing "No" you declare on your honour that you do not have any other interests or facts to declare accordingly.